ETS1 and ovarian carcinoma: Compared to the LV-GFP Exos group, LV-ETS1 Exos boosted ovarian cancer metastasis to the omentum, whereas cilengitide prevented the pro-tumorigenic impact of LV-ETS1 Exos (Fig. 7E–G).